Company / Total Assets
Avalo Therapeutics, Inc. Total Assets History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$116.5M
FY2025
5-year range
$21.0M / $150.7M
FY2021-FY2025
Trend
-22.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has fluctuated over the past 9 years, ranging from $21M in FY2023 to $151M in FY2024.
Based on SEC 10-K filings.
$116M in FY2025 with a 5-year CAGR of +21.6%.
Improved from $21M to $116M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- +51.7%
- 5-Year CAGR
- +21.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +21.6%, indicating consistent growth.
- In FY2025, total assets decreased 22.7% year-over-year.
- Peak total assets was recorded in FY2024.
- Lowest total assets in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $116.5M | -22.7% |
| FY2024 | $150.7M | +618.0% |
| FY2023 | $21.0M | -37.1% |
| FY2022 | $33.4M | -58.4% |
| FY2021 | $80.2M | +83.3% |
| FY2020 | $43.8M | +21.2% |
| FY2019 | $36.1M | -48.6% |
| FY2018 | $70.3M | +64.1% |
| FY2017 | $42.8M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026